(2S,3S)-2-benzhydryl-N-[[2-methoxy-5-(2-methylpropyl)phenyl]methyl]-1-azabicyclo[2.2.2]octan-3-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3S)-2-benzhydryl-N-[[2-methoxy-5-(2-methylpropyl)phenyl]methyl]-1-azabicyclo[2.2.2]octan-3-amine
• 化学式: C₃₂H₄₀N₂O
• 分子量: 468.7
• InChiKey: PPVHHAMRGDSFNW-ACHIHNKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• MAROPITANT FORMULATION
  申请人：Le Vet B.V.

  公开号：EP3173071A1

  公开（公告）日：2017-05-31

  The present invention relates to a pharmaceutical composition comprising an aqueous solution of maropitant citrate a pharmaceutically acceptable β-cyclodextrin, 7 - 18 mg/ml of a pharmaceutically acceptable preservative, a method for preparing said composition, comprising the steps of mixing, in an aqueous medium, a source of maropitant, a source of citrate, a pharmaceutically acceptable β-cyclodextrin and a pharmaceutically acceptable preservative. The invention also relates to the use of the said composition as a medicament.

  本发明涉及一种药物组合物，该组合物包括枸橼酸马罗匹坦的水溶液、药学上可接受的β-环糊精、7-18 mg/ml的药学上可接受的防腐剂，制备所述组合物的方法包括以下步骤：在水介质中混合马罗匹坦、枸橼酸源、药学上可接受的β-环糊精和药学上可接受的防腐剂。本发明还涉及上述组合物作为药物的用途。
• Novel Method
  申请人：Ferrari Giulio

  公开号：US20140128395A1

  公开（公告）日：2014-05-08

  There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.